Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 4

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 2(2)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04294277Phase 2Terminated

Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery

Role: collaborator

NCT03355157Phase 4Completed

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

Role: collaborator

NCT04170309Completed

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

Role: collaborator

NCT03696901Terminated

Xydalba Utilization Registry in Germany

Role: collaborator

NCT03347370Completed

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis

Role: collaborator

NCT02957851Phase 2Completed

EMONO for the Treatment of Peripheral Neuropathic Pain